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Summary Inhibitors of kinesin spindle protein Eg5 are char-
acterized by pronounced antitumor activity. Our group has
recently synthesized and screened a library of 1,3,4-
thiadiazoline analogues with the pharmacophoric structure of
K858, an Eg5 inhibitor. We herein report the effects of K858
on four different breast cancer cell lines: MCF7 (luminal A),
BT474 (luminal B), SKBR3 (HER2 like) and MDA-MB231
(basal like). We demonstrated that K858 displayed anti-
proliferative activity on every analyzed breast cancer cell line
by inducing apoptosis. However, at the same time, we showed
that K858 up-regulated survivin, an anti-apoptotic molecule.
We then performed a negative regulation of survivin expres-
sion, with the utilization of wortmannin, an AKT inhibitor,
and obtained a significant increase of K858-dependent apo-
ptosis. These data demonstrate that K858 is a potent inhibitor
of replication and induces apoptosis in breast tumor cells,
independently from the tumor phenotype. This anti-
proliferative response of tumor cells to K858 can be limited
by the contemporaneous over-expression of survivin; conse-
quently, the reduction of survivin levels, obtained with AKT
inhibitors, can sensitize tumor cells to K858-induced
apoptosis.
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Introduction
Mitotic kinesins are important regulators of cancer cell repli-
cation and migration [1], since these proteins play an impor-
tant role in the formation of the bipolar mitotic spindle and in
the regulation of cell cycle progression [2]. The nuclear
kinesin Eg5 (Kindle Spindle Protein/KSP/KIF11) is over-
expressed in many solid tumors and covers an important part
in tumorigenesis [3]. Monastrol was the first to be studied
among these compounds [4], but also other small similar mol-
ecules, capable to arrest cell replication, have been more re-
cently described [5, 6]. These agents cause arrest of mitosis by
damaging monopolar spindle and consequently causing cell
death [7]; some cells treated with kinesin inhibitors arrest in
G1-like phase and die for apoptosis by a specific tetraploidy
checkpoint [8]. The negative regulation of Eg5 is capable to
arrest the replication of hepatocellular carcinoma [9], glioblas-
toma [10] and prostate cancer cells [11] in vitro, suggesting
that Eg5 inhibition can be a potential target for anti-cancer
therapy.
Several compounds that inhibit kinesins have been studied
in clinical trials [12, 13], unfortunately with poor benefits, in
opposite to successful results obtained in pre-clinical research
on neoplastic cells [9–11]. Among Eg5-inhibitors, ispinesib
has been shown to share the mode of action with monastrol
[14], however its clinical utilization led to conflicting results.
A group of 24 patients affected by different solid tumors was
treated with ispinesib and docetaxel and 7 patients had a good
response with a stable disease (SD) for ≥18 weeks in a phase I
study [15]; but, at the same time, no patients with androgen-
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independent and docetaxel-resistant prostate cancer gave re-
sponses to ispinesib monotherapy in a phase II study [16].
Probably, the development of chemoresistance can limit
the anti-neoplastic performance of kinesin inhibitors. For this
reason, more studies are needed to understand why in vivo
results are so disappointing; it should be explored whether a
process of chemoresistance is triggered by Eg5-inhibiting
compounds, as happens for taxanes. In fact, anti Eg5 agents
can be considered novel taxanes, since both molecules target
the microtubules of the cytoskeleton and lead to mitotic arrest
and apoptosis [17]. Unfortunately, taxanes are characterized
by many side effects, such as the neurotoxicity [18, 19], be-
sides the chemoresistance, which determine the limitation of
the use of these chemotherapeutics in all cancer patients.
Therefore, there is an urgent unmet need to find anti-mitotic
molecules that overcome taxane resistance; to this purpose, an
inhibitor of Eg5 has demonstrated to overtake drug resistance
in two taxane resistant cancer cell lines [20].
Our group has recently synthesized and screened a library
of 1,3,4-thiadiazoline analogues, all characterized by the
pharmacophoric structure of K858 [21], which is a newly
discovered inhibitor of kinesin Eg5, capable to induce the
mitotic arrest in several types of cancer cells [22]. In this
previous research we screened the anti-proliferative activity
of 103 derivatives of K858 on prostate cancer and melanoma
cell lines and identified two compounds as the most effective,
one corresponding to unmodified K858 and the other corre-
sponding to a derivative where the methyl group in C5 of
K858 was substituted with an ethyl group [21]. In the present
work, we used the described compound corresponding to un-
changed K858 and tested its efficacy in inducing cell death on
different phenotypes of breast cancer. In parallel, since we
recently demonstrated a significant correlation between resis-
tance to taxane and up-regulation of survivin in the same cells
[23], we evaluated the possible role of survivin in the estab-
lishment of chemoresistance to K858.
Materials and methods
Cell culture and treatments
The following four human breast cancer cell lines have been
utilized: MCF7 (Luminal A: estrogen receptor-positive and
progesterone receptor-positive, ErbB2-negative), BT474
(Luminal B: estrogen receptor/progesterone receptor/ErbB2-
positive) SKBR3 (HER2 like: estrogen receptor-negative/pro-
gesterone receptor-negative, ErbB2-positive) and MDA-
MB231 (Basal like: estrogen receptor/progesterone receptor/
ErbB2-negative). All cell lines were grown in DMEM medi-
um supplemented with 10 % fetal calf serum (FCS), 2 mM
glutamine, 50 U/mL penicillin-streptomycin and starved,
when necessary, in DMEM medium with 2 % dialyzed FCS.
K858 was synthesized, characterized and utilized as
previously described [21], K858 was solubilized in
dimethylsulfoxide (DMSO) at 1 mM stock solution and uti-
lized to final concentration of 10 μM. Wortmannin (Sigma)
was solubilized in DMSO at 10 mM stock solution and used
100 nM.
Cytotoxicity assay
To determine cytotoxicity, sulforhodamine B colorimetric as-
say was performed: 1.5X104 cells were plated on 96 well
plates, grown for 24 h (h) and treated with different concen-
trations of K858 (1 μM, 10 μM, 100 μM) for 24 and 48 h.
Cells were then fixed with 50 % trichloroacetic acid for 1 h at
4 °C and stained for 30 min at room temperature (RT) with
0.4 % sulforhodamine B in 1 % acetic acid. Excess dye was
removed by washing four times with 1 % acetic acid. Protein-
bound dye was dissolved in 10 mM TRIS pH 10, and optical
density (OD) was determined at 510 nm using a microplate
reader.
Western blot
Cell lysates were obtained scraping the cells in lysis buffer
1 % Triton, 0.1 % SDS, 150 mM NaCl, 50 mM TRIS-HCl
pH 7.4, 2 mM EDTA plus protease inhibitor cocktail tablet
(Roche Applied Sciences) for 30 min at 4 °C, lysates were
then centrifuged at 12,000 rpm for 15 min at 4 °C. Protein
concentrat ion was evaluated by Bio-Rad Protein
Concentration Assay. Samples of lysate (50-100 μg) were
separated by molecular weight on 10 or 12 % SDS-PAGE
and then transferred into a nitrocellulose membrane. Blots
were blocked for 1 h at RT in 5 % non-fat dry milk and then
incubated with primary antibody, washed in TRIS-buffered
saline with 0.1 % Tween 20 and then incubated with
horseradish peroxidase conjugated anti-mouse or anti-
rabbit antibodies (1:5000 diluted) (Sigma-Aldrich). The
filters were then developed by enhanced chemilumines-
cence (Super Signal West Pico Chemiluminescent Substrate,
Thermo Scientific) using Kodak X-Omat films. The densi-
tometry quantitation of the bands was performed using
Image J software.
The primary antibodies were the following: rabbit
anti survivin (1:1000 diluted) (Novus Biological,
Littleton, CO, USA); rabbit anti cleaved caspase-8
(1:500 diluted) (Cell Signaling); mouse anti cleaved caspase
9 (1:500 diluted) (Cell Signaling); mouse anti Parp1 (1:500
diluted) (Santa Cruz Biotechnology); mouse anti bcl2
(1:250 diluted); rabbit anti bax (1: 250 diluted) (BD
Transduction Laboratories USA); mouse anti-actin (1:1000
diluted) (Sigma Aldrich).
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Reverse transcriptase polymerase chain reaction
(RT-PCR) assay
Total RNA from the cells was isolated using Trizol reagent
(Invitrogen, Carlsband, CA) according to the manufacturer’s
instructions; Moloney murine leukemia virus (M-MLV) re-
verse transcriptase (Biolab) was used to reverse 1 μg of total
RNA into cDNA at 42 °C. 5 μg of each cDNA was then
subjected to RT-PCR in a buffer containing 25 pmol of up-
stream and downstream and 1.25 U of Platinum Taq polymer-
ase (Euroclone). The amount of amplified products, expressed
in arbitrary optical density units, was normalized with
glyceraldehyde-3-phosphate dehydrogenase (GADPH) as
housekeeping gene. The amplification reaction was carried
out in Piko-Thermal Cycler cyclers (Finnzymes Instrument).
The resulting PCR products were separated in 2 % agarose gel
and visualized with Gel-Red (Gel Red nucleic acid gel stain,
Biotium). The sequences of human gene-specific primers
(Sigma-Aldrich) with order of forward and reverse, the con-
ditions of amplification as well as the amplified products size
are the following: Gadph: 5-AGATGTTCCAATATGATTCC,
5′-TGGACTCCACGACGTACTCAG; 60 °C; 161 bp.
B c l - 2 : G T G G A G G A G C T C T T C A G G G A ,
AGGCACCCAGGGTGATGCAA; 60 °C; 304 bp.
B a x : G G C C C A C C A G C T C T G A G C A G A ,
GCCACGTGGGCGTCCCAAAGT; 62 °C; 469 bp.
Su r v i v i n : CAGATTTGAATCGCGGGACCC ,
CCAAGTCTGGCTCGTTCTCAG; 60 °C; 206 bp.
Cell apoptosis assay
The cells were treated with 10 μM K858 for 24 h. Both de-
tached and adherent cells were harvested by trypsin-EDTA
and washed with cold phosphate buffered saline. The cells
were double stained with AnnexinV-APC (allophycocyanin)/
7AAD (7-amino-actinomycin) in a calcium binding buffer
(BD Biosciences kit) and analyzed by a FACS scan
cytofluorimeter (BD Biosciences).
Statistical analysis and graphic programs
All results were analyzed by ANOVA, and the significance
was evaluated by the Tukey HSD post hoc test (Honestly
Significant Difference). All figures were elaborated with
Adobe Photoshop CS5 and all graphs with Graph Pad Prism
5.0.
Results
We first investigated the effects of K858 on cell viability and
replication: MCF7, MDA-MB231, BT474 and SKBR3 cell
lines were treated for 24 and 48 h with 1 μM, 10 μM,
100 μM K858. At 24 h of treatment, K858 determined a
decrease of cell viability in all four cell lines; this decrease
was significant at all three used concentrations for three cell
lines, while MDA-MB231 had a decrease of cell viability
significant at 10 and 100 μM, but not significant at 1 μM
(Fig. 1). The described effects on cell viability were similar
when the cells were treated with K858 for 48 h, without any
significant variation as compared to 24 h of treatment (data not
shown). Based on these data, K858 was used for the following
experiments at the concentration of 10μM for 24 h. In order to
detect whether the described cell loss was due to apoptosis,
K858 treated and untreated cells were evaluated for PARP
(poly ADP-ribose polymerase), which is usually cleaved by
caspase 3 during the last phases of apoptosis: K858 deter-
mined PARP cleavage in all four cell lines, as evidenced by
the cleaved band present only in the treated cells by western
blot analysis (Fig. 2); this result demonstrated that K858 was
able to induce apoptosis. Following, the cleavage of caspase 8
and 9 was studied, since the presence of proteolytic fragments
of caspases is an index of their activation and of consequent
apoptosis: caspase 9 resulted cleaved in all four K858 treated
cell lines, and caspase 8 was cleaved in BT474 and SKBR3
treated cell lines, while it was not expressed byMDA-MB231
andMCF7 cell lines (Fig. 2). These data suggested thatMDA-
MB231 and MCF7 cells followed an intrinsic pathway of
apoptosis, characterized by the cleavage of caspase 9, while
BT474 and SKBR3 had activated both intrinsic and extrinsic
pathways.
To better analyze the apoptosis determined by K858, the
expression of Bax (an apoptosis inducer) and of Bcl2 (an
apoptosis inhibitor) was then quantified, since an increase in
Bax/Bcl2 ratio is often described during apoptosis. As expect-
ed, an increase of Bax/Bcl2 ratio was evident in all four K858
treated cell lines, as evaluated by western blot and subsequent
densitometry analysis of the bands (Fig. 3a–b). In parallel,
Bax and Bcl2 RNA expression was analyzed by RT-PCR
and resulted that K858 enhanced Bax/Bcl2 RNA ratio in all
four cell lines (Fig. 3c).
In order to evaluate whether the cell loss induced by K858
was due also to necrosis, in addition to apoptosis, we double
stained untreated and K858 treated cells with APC conjugated
annexin V and with 7AAD and analyzed by fluorescence ac-
tivated cell sorter (FACS): K858 treatment determined a high
rate of annexin V staining in all four cell lines, indicative of
apoptosis (Fig. 4). As positive control of apoptosis, all four
cell lines were treated with staurosporine (an apoptosis induc-
er), and all staurosporine treated lines resulted highly positive
for annexin V expression (data not shown).
Finally, we investigated the expression of survivin, which
has been recently described as enhanced by monastrol, a
kinesin-5 inhibitor molecule [24], in cancer cells. K858 treat-
ment determined an up-regulation of survivin in all four cell
lines, as evidenced by western blot, with a statistically
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significant increase (p = 0,002) (Fig. 5); these data were con-
firmed by RT-PCR, with an evident enhancement of survivin
RNA levels in all four K858 treated cell lines (Fig. 5).
Apparently, this up-regulation of survivin was in contrast
with the described apoptosis induced by K858; so, we then
investigated whether survivin increased expression could neg-
atively interfere with K858-dependent apoptotic response.
Therefore, we inhibited survivin expression by treating
MCF7 cells with 100 nM wortmannin, an inhibitor of
phosphoinositide 3-kinase AKT (PI3K/AKT), since it is well
known that Akt activation is required for survivin expression
[25], and we recently demonstrated that wortmannin is able to
negatively regulate survivin in the same cell lines [23]. As
expected, the up-regulation of survivin determined by K858
treatment in MCF7 cells was totally reversed by wortmannin
addition, as demonstrated by western blot (K858 treated ver-
sus K858 plus wortmannin treated cells) (Fig. 6). In the same
experiment, the treatment with wortmannin together to K858
determined a significant increase of Bax/Bcl2 ratio and an
increase of 41 % of cleaved PARP, as compared to the treat-
ment with K858 alone, demonstrating an increased apoptosis
rate contemporaneous to the inhibition of survivin (Fig. 6).
These data suggested that, reducing survivin expression by
wortmannin, tumor cells were more sensitized to K858-
dependent apoptosis.
Discussion
Kinesin inhibitors have anti-proliferative properties and they
can lead cancer cells to mitotic arrest and apoptosis, or in G1
phase by mitotic slippage until apoptosis, caused by a tetra-
ploidy checkpoint [8]. Although promising results have been
recently obtained on breast cancer cells in vitro [26, 27] and on
Fig. 1 Cell viability of untreated
(ctr) and K858 treated breast
cancer cell lines expressed as
percentage of alive cells in a
graph and in a table
Fig. 2 Western blot of untreated
and K858 treated (T) breast
cancer cell lines for PARP,
caspase 8, caspase 9 and actin
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Fig. 3 aWestern blot of
untreated and K858 treated (T)
cell lines for Bax, Bcl2 and actin.
b Histogram of Bax/Bcl2 protein
ratio in untreated (C) and K858
treated (T) cells performed on the
densitometry quantifications of
Bax and Bcl2 protein bands upon
normalization to actin. c
Histogram of Bax/Bcl2 RNA
ratio in untreated (C) and K858
treated (T) cells, performed on the
densitometry quantifications of
Bax and Bcl2 RT-PCR RNA
bands upon normalization to
GAPDH
Fig. 4 Annexin V-APC and
7AAD expression evaluated by
FACS. a The upper dot blots
represent untreated cells (C) and
the lower dot blots K858 treated
cells (T). Quadrant location for
the representative dot blots: lower
left - living cells, lower and upper
right - apoptotic cells, upper left -
necrotic cells. b Each bar
represents the percentage of
apoptotic (grey) and necrotic
(black) untreated (first column)
and K858 treated (second
column) cells expressed as mean
+/−SD of three different
experiments
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breast cancer models in animals [28], limited results have been
confirmed in clinical trials with cancer patients: for example, a
phase I trial with ispinesib on 16 breast cancer patients obtain-
ed only 9 % of response rate, although it demonstrated a low
range of toxicity of this therapy [29]. A recent work showed
that a new compound with Eg5 inhibition activity was able to
impair the proliferation of breast cancer cells and also to de-
crease the cancer stem cell number within the tumor [30].
Therefore, we have tested some effects of the kinesin in-
hibitor K858 on breast cancer cell lines, corresponding to four
different molecular phenotypes, and found that all four phe-
notypes responded to K858 with a significant apoptosis rate.
In particular, triple negative and luminal A cells followed
mainly the intrinsic pathway of apoptosis, while luminal B
and HER2 like cells had activated both intrinsic and extrinsic
pathways. However, we found that K858 induced up-
regulation of the anti-apoptotic molecule survivin; at this re-
gard, we have recently demonstrated that an increase of
survivin expression is one of the mechanisms at the basis of
chemoresistance to taxane in breast cancer cells [23]. Another
recent study reported that the over-expression of survivin in
cancer cell lines treated with the kinesin-5 inhibitor monastrol
increased the resistance to monastrol [24]. The implication of
survivin in the chemoresistance process can be also supported
by the description that its down-regulation is associated to
mitotic slippage in the presence of spindle damage [31].
Survivin expression is described in several tumors, and its
up-regulation usually correlates with the worst prognosis in
breast cancer, in fact survivin is a key molecule among the
inhibitor of apoptosis (IAP) family of proteins [32]. The main
activation pathway of survivin in breast cancer cells is
PI3K/AKT/mitogen-activated protein kinase MAPK, which
may cross-react and strengthen other pathways, such as the
estrogen pathway (PI3K/AKT/mammalian target of
rapamycin mTOR) [25, 33], reinforcing the signal transduc-
tion mediated by hormone receptors, with the onset of contin-
uous stimulation on hormone-responsive tumor cells. For this
reason we have utilized wortmannin, an inhibitor of
PI3K/AKT, which negatively regulates survivin, trying to re-
duce chemoresistance and to improve the efficacy of K858
treatment. In fact, we found that, turning off the survivin path-
way, breast cancer cells were more sensitized to K858-
mediated apoptosis.
Our data substantially confirm the role played by survivin
in inducing resistance to kinesin inhibitors, and suggest that
the efficacy of anti-cancer treatment with K858 can be im-
proved by silencing survivin expression. These findings
Fig. 5 Regulation of survivin
expression and transcription by
K858: Western blot of survivin
and actin (first and second rows)
on untreated and K858 treated (T)
breast cancer cell lines; RT-PCR
of survivin and GADPH mRNA
(third and fourth rows) in the
same cells
Fig. 6 Western blot of survivin, Bax, Bcl2, PARP and actin on untreated
(CT), K858 treated, wortmannin (WT) and K858 plus wortmannin
(WT + K858) treated MCF7 cells. The densitometry quantitation is
indicated for Bax/Bcl2 ratio and for cleaved PARP
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underline a potential synergic activity of kinesin inhibitors
with AKT inhibitor molecules, with the target to overcome
chemoresistance in breast cancer cells.
Although taxanes and kinesin inhibitors share the mecha-
nisms of action in blocking tumor growth, an important clin-
ical aspect differentiates one agent from the other, since
taxane can cause neuropathy [18], while kinesin inhibitors
present a good tolerability without neurotoxicity [16, 29, 34].
Unfortunately, neuropathy is very common (accounting for
more than 80 %) in breast cancer patients treated with taxanes
and neurotoxicity is an important dose limiting side effect of
taxanes, frequently causing the discontinuation of docetaxel or
paclitaxel treatment in cancer patients. So, it is important to
find alternative molecules among anti-mitotic agents microtu-
bule-targeted, which exert a significant anti-neoplastic activity
without serious side effects.
More investigations are needed to study in deep the effi-
ciency of K858 treatment on breast cancer cells, with the aim
to find out the mechanisms capable to negatively regulate
survivin expression on multiple fronts and to improve kinesin
inhibitors as potential not neurotoxic but effective new anti-
cancer drugs.
Conclusion
Our experiments demonstrate that K858 displays anti-
proliferative activity through the induction of apoptosis in
breast cancer cells but, at the same time, unfortunately, K858
exerts a stimulation of survivin expression, which finally leads
to resistance. These data suggest that K858 can have a poten-
tial role as anti-cancer agent, probably improvable by the ad-
dition of survivin/AKT inhibitors. This information is sup-
portive to future clinical investigations on the utilization of
kinesin inhibitors for the treatment of breast cancer.
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